PD-L1 expression and clinical outcomes to cabozantinib, everolimus and sunitinib in patients with metastatic renal cell carcinoma: analysis of the randomized clinical trials METEOR and CABOSUN

PURPOSE: PD-L1 status by immunohistochemistry (IHC) is prognostic in metastatic renal cell carcinoma (mRCC) and its role as a potential predictive biomarker is under investigation. Using tumor tissue from the METEOR () and CABOSUN () clinical trials, we explored whether PD-L1 expression and the exte...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Flaifel, Abdallah, Xie, Wanling, Braun, David A., Ficial, Miriam, Bakouny, Ziad, Nassar, Amin H., Jennings, Rebecca B., Escudier, Bernard, George, Daniel J., Motzer, Robert J., Morris, Michael J., Powles, Thomas, Wang, Evelyn, Huang, Ying, Freeman, Gordon J., Choueiri, Toni K., Signoretti, Sabina
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6801080/
https://ncbi.nlm.nih.gov/pubmed/31371341
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1135
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados